177 results about "Cardiac failures" patented technology

Method and apparatus for the treatment of cardiac failure, Cheyne Stokes breathing or central sleep apnea are disclosed. A subject is provided with ventilatory support, for example positive pressure ventilatory support using a blower and mask. Respiratory airflow is determined. From the respiratory airflow are derived a measure of instantaneous ventilation (for example half the absolute value of the respiratory airflow) and a measure of longterm average ventilation (for example the instantaneous ventilation low pass filtered with a 100 second time constant). A target ventilation is taken as 95% of the longterm average ventilation. The instantaneous ventilation is fed as the input signal to a clipped integral controller, with the target ventilation as the reference signal. The output of the controller determines the degree of ventilatory support. Clipping is typically to between half and double the degree of support that would do all the respirator work. A third measure of ventilation, for example instantaneous ventilation low pass filtered with a time constant of 5 seconds, is calculated. Ventilatory support is in phase with the subject's respiratory airflow to the fuzzy extent that this ventilation is above target, and at a preset rate conversely.

The present invention provides a drug for at least one of prevention and treatment of cardiac failure capable of suppressing cardiac depression and the onset of cardiac failure in ventricular remodeling, and a method for screening the drug. The drug for at least one of prevention and treatment of cardiac failure of the present invention contains a compound that inhibits a functional expression of ASK1 protein in a cardiomyocyte as an active ingredient, and a method for screening a drug for at least one of prevention and treatment of cardiac failure of the present invention includes selecting a medicinal component for at least one of prevention and treatment of cardiac failure from a drug candidate compound by using inhibition of a functional expression of ASK1 protein as an indication. As shown in FIG. 1, if ASK1 protein is removed, for example, the ventricle dilation can be attenuated in ventricular remodeling after myocardial infarction, pressure loading, or the like, which makes it possible to prevent and treat cardiac failure.

The present invention relates to multipotent stem cells derived from the interstitial tissues of skeletal muscle. The multipotent stem cell of the present invention is capable of differentiating into skeletal muscle cells, smooth muscle cells, cardiomyocytes, blood cells, vascular endothelial cells, adipocytes, osteoblasts, nervous cells, hepatocytes and pancreatic cells, and is useful for regeneration of tissues and cells and treatment for cardiac failure, hepatic insufficiency, renal insufficiency, leukemia, nerve degeneration disease, arthritis, diabetes, arteriosclerosis, and the like.

A Minimally Invasive Ventricular Assist Device for circulatory support of a failing heart apt to be inserted percutaneously bluntly via a thoracostomy a into a chest cavity of a patient in cardiac failure or cardiac arrest without the need for wide surgical opening of the chest. The device once deployed inside the chest is capable of compressing and decompressing the heart via pneumatic or mechanical means providing circulatory support to patients in cardiac failure or cardiac arrest. Due to its design and structure the Minimally Invasive Percutaneous Ventricular Assist Device can be deployed rapidly and safely at bedside by health care professionals properly trained in the procedure.

The invention relates to a heart impulse assisting device which comprises a heart ventricle capacity regulating device used for regulating the heart ventricle capacity, a synchronizer used for acquiring a heart ventricle contracting signal, and a control device used for receiving the heart ventricle contracting signal acquired by the synchronizer, wherein a sensor of the synchronizer is connectedto the heart; the synchronizer is internally provided with an automatic defibrillation device and a synchronization treatment device, a defibrillation electrode of the automatic defibrillation deviceis connected to the heart, and a pacing electrode of the synchronization treatment device is planted into the heart. The heart ventricle capacity regulating device of the heart impulse assisting device has small volume, thus the heart impulse assisting device can be planted inside the heart, can fully simulate the heart ventricle pressure capacity change rule and the heart synchronous impulse works, and can be used for assisting the heart impulse acting to treat the cardiac failure, form the heart ventricle and repair the perforation of ventricular septum.

The invention discloses a novel Chinese medicinal composition for treating cardiac failure and a preparation method thereof. The Chinese medicinal composition of the invention mainly comprises the following raw material medicaments: kudzu-vine root, tangerine peel, green tangerine peel, immature bitter orange, costustoot, cyperus rotundus, szechwan chinaberry fruit, aspongopus, Chinese eaglewood, cassia bark, medcinal evodia fruit, lesser galangal rhizome, szechuan lovage rhizome, yanhusuo, danshen root, sanchi, turmeric root-tuber, curcuma longa, frankincense, myrrh, safflower, peach seed, motherwort herb, twotooth achyranthes root, common burreed rhizome, zedoary, mix-fried pangolin scales, ginseng, American ginseng, raw raidx astragali, pilose asiabell root, white paeony root, common yam rhizome, Chinese angelica, storax, toad venom, grassleaf sweelflag rhizome, borneol, camphor, musk, Chinese caterpillar fungus, cherokee rose fruit, desertliving cistanche, radix rehmanniae preparata, tuber fleeceflower root, root of straight ladybell, barbary wolfberry fruit, mix-fried turtle shell, mix-fried tortoise plastron, agastache and villous amomum fruit. The Chinese medicinal composition of the invention can be prepared into a normal oral preparation by the common Chinese medicament preparation method. The Chinese medicinal composition can obviously improve tireness and hypodynamia, decompensation, chest distress and dyspnea, cough, wheezing, limb oedema, jugular vein distention and inappetence, and has exact and obvious curative effect and quick response. The Chinese medicinal composition of the invention basically adopts medicinal and edible medicaments specified by the National Formulary to carry out combination, thus, the Chinese medicinal composition has the advantages of low price, basically no toxic or side effects and the like.

The invention provides an MG53 (mitsugumin53) mutant and a preparation method thereof. The mutant is a serine-site mutant of MG53 protein in a Coiled-coil structural domain, and the mutant results in inactivation of MG53 phosphorylation. Meanwhile, the MG53 protein mutant can be used for preventing or treating diseases related to cellular membrane damage, such as diseases related to myocardial cell injury, diseases related to ulcer, trauma with a wound, particularly a difficult-to-heal wound, intestinal leakage, kidney injury and the like. The diseases related to myocardial cell injury can include one or more diseases related to following symptoms: myocardial ischemia, heart ischemia, heart ischemia/reperfusion injury, myocardial infarction, cardiac failure, arrhythmia and cardiac rupture. The diseases related to ulcer include one or more of following diseases: chronic ulcer, peptic ulcer, diabetic foot ulcer, diabetic foot gangrene and chronic gastric ulcer. Besides, the invention further provides a dry powder preparation, a spray preparation, a gel preparation and an emulsion containing MG53 or MG53 mutant as well as preparation methods of the preparations.

The present invention relates to a stable pharmaceutical composition comprising an ACE inhibitor or a pharmaceutically acceptable salt or derivative thereof. In particular, the invention relates to a pharmaceutical composition, which comprises an ACE inhibitor, or a pharmaceutically acceptable salt or a derivative thereof, and a C₁₆-C₂₈ glyceride. ACE inhibitors useful in the present invention are susceptible to heat and/or mechanical stress-induced degradation. Preferred ACE inhibitors are ramipril, trandolapril, quinapril and pharmaceutically acceptable salts and derivatives thereof. The composition of the present invention may be for use as a medicament for the treatment or prevention of a cardiovascular disease, a coronary heart disease, a cerebrovascular disease, a peripheral vascular disease, arrhythmia, hypertension, cardiac failure, cardiovascular death, myocardial infraction, stroke or angina. The present invention further relates to a method of preparing the pharmaceutical composition of the present invention. The present invention also relates to a method of providing a stable pharmaceutical composition comprising an ACE inhibitor, or a pharmaceutically acceptable salt or derivative thereof, by incorporating a C₁₆-C₂₈ glyceride into the composition. The present invention further relates to a use of C₁₆-C₂₈ glyceride to provide a stable pharmaceutical composition comprising an ACE inhibitor or a pharmaceutically acceptable salt or derivative thereof.

The invention relates to a traditional Chinese pharmaceutical composition for treating cardiac failure and process for preparation, wherein the composition is prepared from the following medicinal raw materials (by weight portion): red ginseng 338-413 parts, monkshood 1013-1238 parts, poria cocos wolf 1013-1238 parts, lepidium seed 675-825 parts, notoginseng 563-688 parts, ophiopogon root 675-825 parts, the preparing process comprises mixing red ginseng, prepared aconite root, poria cocos, lepidium seed, notoginseng and ophiopogon root, charging water, grilling twice, merging the grilling liquid and filtering, concentrating the filtrate to clear grease with specific gravity of 1.07-1.10/60 Deg C, spray drying the clear grease, charging medicinal auxiliary materials, pelleting or packing capsules or making granules.

The invention discloses a medicine for treating cardiocerebrovascular diseases, which is mainly prepared by the following raw materials: coenzyme Q10 (CoQ10), Vitamin E (VE) and soybean lecithin (PC). The medicine is widely used for treating coronary heart disease, cardiac failure, arrhythmia, rheumatic heart disease, viral myocarditis, blood supply deficiency, high blood pressure, and other cardiocerebrovascular diseases and periodontitis resulted from gingival atrophy and also can be used as adjuvant therapy for acute and chronic viral hepatitis and cancer, which also has the efficacies of decreasing blood lipid, lowering cholesterol, regulating internal secretion, eliminating climacteric syndrome, resisting aging, preventing senile dementia, etc. In addition, the invention also discloses a production method for preparing the medicine for treating cardiocerebrovascular diseases with semisynthetic raw material.

The invention relates to an application of catalpol in preparing a drug for treating cardiac failure diseases, namely a new application of reacted catalpol in the field of pharmacodynamic activity. The catalpol has the effect of resisting the cardiac failure. In the invention, a traditional Chinese medicine injection prepared by the catalpol is applied to treating the cardiac failure diseases.

The invention discloses a cardiac impulse assist system, which comprises a ventricular volume regulating device, a synchronizer and a control device, wherein the ventricular volume regulating device is used for regulating ventricular volumes; a sensor of the synchronizer is connected to the heart; the synchronizer is used for collecting ventricular systole signals; and the control device is used for receiving the ventricular systole signals collected by the synchronizer, and is used for controlling the ventricular volume regulating device to synchronously reduce the ventricular volumes when ventricular systole is performed. An automatic defibrillating device and a synchronous treatment device are arranged in the synchronizer; a defibrillating electrode of the automatic defibrillating device is connected to the heart; a pacing electrode of the synchronous treatment device is implanted into a chamber of the heart. As the ventricular volume regulating device is small in size, the cardiac impulse assist system disclosed by the invention can be implanted into the chamber of the heart. The cardiac impulse assist system disclosed by the invention can be used for completely imitating a ventricular pressure-volume change rule, can work synchronously with cardiac impulse, and can be used for assist the heart to pulsate and do work so as to treat cardiac failure, promote ventricular restoration and repair the perforation of ventricular septum.

The invention discloses novel application of dermatopontin in preparing a kit for detecting cardiac failure and a detection kit. Through experimental verification, the DPT of the invention can be used to detect the cardiac failure. A method for rapidly detecting the DPT by using blood serum to estimate end-stage heart diseases in the invention has great clinical significance and popularization significance. The expression on the heat failure group DPT caused by the ARVC is up regulated by 3.5 times. The kit for detecting the cardiac failure, which is prepared by the DPT in the invention, has the advantages of high sensitiveness and specificity and high dilution rate of the blood serum. And compared with the conventional method for detecting the cardiac failure, the method of the inventionhas the advantages of low cost, high efficiency, convenient use and the like.

Disclosed are the use of neuregulin proteins in preparing a medicine for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, and a method for using the medicine. Also provided in the present invention is a method for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, comprising using the medication containing the neuregulin proteins in a special population having the disease or being at risk of having the disease.

Disclosed is a pharmaceutical composition effective for preventing and treating cardiac failure. Specifically disclosed is a pharmaceutical composition containing a carbohydrate degrading enzyme inhibitor as an active ingredient.

The invention relates to a torasemide pharmaceutical composition with stabilization and safety for injection and its preparation method, especially relates to the torasemide pharmaceutical composition used for patients with requirement of rapid diuresis or congestive cardiac failure without oral diuresis, cirrhosis ascites, oedema caused by kidney diseases, the torasemide pharmaceutical composition is an injection preferably. The pharmaceutical composition is composed of active component torasemide, ethanol and polysorbate 80. The torasemide pharmaceutical composition for injection possesses stable pH value and low impurity content, and is capable of effectively raising the treatment effect of the products, minimizing the side reaction, raising the yield, reducing the cost and creating higher benefit.

An application of the alcohol extract of urcaria stem with hooks in preparing the medicines for the target protection to organs, such as heart, kidney, etc, to prevent and treat cardiac failure and renal failure is disclosed.

The invention discloses a traditional Chinese medicine preparation for treating vascular disease, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine preparation comprises active ingredients prepared from the following raw materials of oenothera biennis, hawthorn, kelp, eggplant, radix puerariae, tomato, agilawood, red jujube, ligusticum wallichii, pawpaw, nacre mother of pearl, banana, celery, polygonum multiflorum, fresh ginger and mung bean. The traditional Chinese medicine preparation has the effects of relaxing blood vessels, easing pain and diminishing inflammation, lowering blood lipid and protecting myocardium, shows an obvious effects on treating coronary heart disease, stenocardia, hyperlipidemia, myocardial ischemia, heart irrythmia, cardiac failure and other vascular diseases, is low in cost, fast to act, and free of toxic and side effects, and has the total treatment effective rate up to 97%.